{"status":"ok","message-type":"event-list","message":{"next-cursor":"390c3cf8-b125-4726-a3dc-b95456be949c","total-results":9,"items-per-page":1000,"events":[{"license":"https:\/\/creativecommons.org\/licenses\/by-sa\/4.0\/","obj_id":"https:\/\/doi.org\/10.1073\/pnas.082102799","source_token":"1ad0b713-78ed-4bb9-8d5d-a3c2d163d46f","occurred_at":"2015-03-12T00:00:00Z","subj_id":"https:\/\/lens.org\/011-244-993-409-070","id":"90d2c4c1-b74a-2c92-d708-7c1c1d531fe3","terms":"https:\/\/doi.org\/10.13003\/CED-terms-of-use","action":"add","subj":{"work_subtype_id":"Patent Application","work_type_id":"patent","title":"Method For Improving Antibody Stability","pid":"https:\/\/lens.org\/011-244-993-409-070","jurisdiction":"WO"},"source_id":"cambia-lens","timestamp":"2017-11-10T03:35:01Z","relation_type_id":"cites"},{"license":"https:\/\/creativecommons.org\/licenses\/by-sa\/4.0\/","obj_id":"https:\/\/doi.org\/10.1073\/pnas.082102799","source_token":"1ad0b713-78ed-4bb9-8d5d-a3c2d163d46f","occurred_at":"2013-11-12T00:00:00Z","subj_id":"https:\/\/lens.org\/113-770-159-667-631","id":"2b49ae82-6754-99ed-7246-4ff5e7b4062c","terms":"https:\/\/doi.org\/10.13003\/CED-terms-of-use","action":"add","subj":{"work_subtype_id":"Granted Patent","work_type_id":"patent","title":"Methods Of Affinity Maturing Antibodies","pid":"https:\/\/lens.org\/113-770-159-667-631","jurisdiction":"US"},"source_id":"cambia-lens","timestamp":"2017-11-10T03:55:18Z","relation_type_id":"cites"},{"license":"https:\/\/creativecommons.org\/licenses\/by-sa\/4.0\/","obj_id":"https:\/\/doi.org\/10.1073\/pnas.082102799","source_token":"1ad0b713-78ed-4bb9-8d5d-a3c2d163d46f","occurred_at":"2013-08-01T00:00:00Z","subj_id":"https:\/\/lens.org\/113-857-924-617-191","id":"25eefa16-26a0-b3be-f671-a39fee7e5223","terms":"https:\/\/doi.org\/10.13003\/CED-terms-of-use","action":"add","subj":{"work_subtype_id":"Patent Application","work_type_id":"patent","title":"Stabilized Formulations Containing Anti-Ang2 Antibodies","pid":"https:\/\/lens.org\/113-857-924-617-191","jurisdiction":"WO"},"source_id":"cambia-lens","timestamp":"2017-11-10T03:56:39Z","relation_type_id":"cites"},{"license":"https:\/\/creativecommons.org\/licenses\/by-sa\/4.0\/","obj_id":"https:\/\/doi.org\/10.1073\/pnas.082102799","source_token":"1ad0b713-78ed-4bb9-8d5d-a3c2d163d46f","occurred_at":"2013-12-05T00:00:00Z","subj_id":"https:\/\/lens.org\/139-886-159-834-661","id":"034aabea-bedc-5af3-f29e-db0cedc982c0","terms":"https:\/\/doi.org\/10.13003\/CED-terms-of-use","action":"add","subj":{"work_subtype_id":"Patent Application","work_type_id":"patent","title":"Stabilized Formulations Containing Anti-Dll4 Antibodies","pid":"https:\/\/lens.org\/139-886-159-834-661","jurisdiction":"WO"},"source_id":"cambia-lens","timestamp":"2017-11-10T10:39:37Z","relation_type_id":"cites"},{"license":"https:\/\/creativecommons.org\/licenses\/by-sa\/4.0\/","obj_id":"https:\/\/doi.org\/10.1073\/pnas.082102799","source_token":"1ad0b713-78ed-4bb9-8d5d-a3c2d163d46f","occurred_at":"2013-01-31T00:00:00Z","subj_id":"https:\/\/lens.org\/173-535-016-663-904","id":"43373e39-9d4c-20cf-ee9c-faeefff23273","terms":"https:\/\/doi.org\/10.13003\/CED-terms-of-use","action":"add","subj":{"work_subtype_id":"Patent Application","work_type_id":"patent","title":"Stabilized Formulations Containing Anti-Pcsk9 Antibodies","pid":"https:\/\/lens.org\/173-535-016-663-904","jurisdiction":"WO"},"source_id":"cambia-lens","timestamp":"2017-11-10T19:38:46Z","relation_type_id":"cites"},{"license":"https:\/\/creativecommons.org\/licenses\/by-sa\/4.0\/","obj_id":"https:\/\/doi.org\/10.1073\/pnas.082102799","source_token":"1ad0b713-78ed-4bb9-8d5d-a3c2d163d46f","occurred_at":"2012-04-12T00:00:00Z","subj_id":"https:\/\/lens.org\/008-103-090-189-989","id":"d7769e5a-28cd-10c2-05e6-e8cfc6c1d29e","terms":"https:\/\/doi.org\/10.13003\/CED-terms-of-use","action":"add","subj":{"work_subtype_id":"Patent Application","work_type_id":"patent","title":"Stabilized Formulations Containing Anti-Interleukin-4 Receptor (Il-4R) Antibodies","pid":"https:\/\/lens.org\/008-103-090-189-989","jurisdiction":"WO"},"source_id":"cambia-lens","timestamp":"2017-11-11T19:12:57Z","relation_type_id":"cites"},{"license":"https:\/\/doi.org\/10.13003\/CED-terms-of-use","obj_id":"https:\/\/doi.org\/10.1073\/pnas.082102799","source_token":"8676e950-8ac5-4074-8ac3-c0a18ada7e99","occurred_at":"2012-09-21T00:00:00Z","subj_id":"https:\/\/doi.org\/10.1128\/AEM.01938-12","id":"20473e89-9976-42c2-a28d-3ae9c3a2e842","terms":"https:\/\/doi.org\/10.13003\/CED-terms-of-use","message_action":"create","source_id":"crossref","timestamp":"2019-07-15T00:07:37Z","relation_type_id":"references"},{"license":"https:\/\/doi.org\/10.13003\/CED-terms-of-use","obj_id":"https:\/\/doi.org\/10.1073\/pnas.082102799","source_token":"8676e950-8ac5-4074-8ac3-c0a18ada7e99","occurred_at":"2013-05-01T00:00:00Z","subj_id":"https:\/\/doi.org\/10.4161\/mabs.24458","id":"9718a467-c345-426e-b0d7-94a0772699a4","terms":"https:\/\/doi.org\/10.13003\/CED-terms-of-use","message_action":"create","source_id":"crossref","timestamp":"2019-07-28T00:41:04Z","relation_type_id":"references"},{"license":"https:\/\/doi.org\/10.13003\/CED-terms-of-use","obj_id":"https:\/\/doi.org\/10.1073\/pnas.082102799","source_token":"8676e950-8ac5-4074-8ac3-c0a18ada7e99","occurred_at":"2012-04-01T00:00:00Z","subj_id":"https:\/\/doi.org\/10.1002\/pmic.201100455","id":"390c3cf8-b125-4726-a3dc-b95456be949c","terms":"https:\/\/doi.org\/10.13003\/CED-terms-of-use","message_action":"create","source_id":"crossref","timestamp":"2019-12-10T15:26:24Z","relation_type_id":"references"}]}}